BRPI0714937A2 - forma de dosagem unitÁria oral, e, uso de uma forma de dosagem unitÁria - Google Patents

forma de dosagem unitÁria oral, e, uso de uma forma de dosagem unitÁria Download PDF

Info

Publication number
BRPI0714937A2
BRPI0714937A2 BRPI0714937-9A BRPI0714937A BRPI0714937A2 BR PI0714937 A2 BRPI0714937 A2 BR PI0714937A2 BR PI0714937 A BRPI0714937 A BR PI0714937A BR PI0714937 A2 BRPI0714937 A2 BR PI0714937A2
Authority
BR
Brazil
Prior art keywords
famotidine
ibuprofen
dosage form
tid
administration
Prior art date
Application number
BRPI0714937-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Tidmarsh George
L. Golombik Barry
Sharma Puneet
Original Assignee
Horizon Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/489,269 external-priority patent/US20080021078A1/en
Priority claimed from US11/489,272 external-priority patent/US20080020040A1/en
Application filed by Horizon Therapeutics, Inc. filed Critical Horizon Therapeutics, Inc.
Publication of BRPI0714937A2 publication Critical patent/BRPI0714937A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0714937-9A 2006-07-18 2007-07-17 forma de dosagem unitÁria oral, e, uso de uma forma de dosagem unitÁria BRPI0714937A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11/489269 2006-07-18
US11/489,269 US20080021078A1 (en) 2006-07-18 2006-07-18 Methods and medicaments for administration of ibuprofen
US11/489,272 US20080020040A1 (en) 2006-07-18 2006-07-18 Unit dose form for administration of ibuprofen
US11/489272 2006-07-18
US89737107P 2007-01-24 2007-01-24
US60/897371 2007-01-24
PCT/US2007/073716 WO2008011426A2 (en) 2006-07-18 2007-07-17 Methods and medicaments for administration of ibuprofen

Publications (1)

Publication Number Publication Date
BRPI0714937A2 true BRPI0714937A2 (pt) 2013-03-26

Family

ID=38957561

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0714937-9A BRPI0714937A2 (pt) 2006-07-18 2007-07-17 forma de dosagem unitÁria oral, e, uso de uma forma de dosagem unitÁria

Country Status (13)

Country Link
EP (2) EP2438919A1 (enExample)
JP (1) JP2009543885A (enExample)
AT (1) ATE539747T1 (enExample)
AU (1) AU2007275360B2 (enExample)
BR (1) BRPI0714937A2 (enExample)
CA (1) CA2657928C (enExample)
DK (1) DK2043637T3 (enExample)
ES (1) ES2380747T3 (enExample)
IL (1) IL196425A (enExample)
NZ (1) NZ574200A (enExample)
PL (1) PL2043637T3 (enExample)
PT (1) PT2043637E (enExample)
WO (1) WO2008011426A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008091957A2 (en) * 2007-01-24 2008-07-31 Horizon Therapeutics, Inc. Pharmaceutical compositions containing famotidine and ibuprofen and having improved content uniformity
WO2013054352A1 (en) 2011-08-17 2013-04-18 Cadila Healthcare Limited Pharmaceutical compositions of ibuprofen and famotidine
EP2912193B1 (en) 2012-10-29 2018-08-29 Arizona Board of Regents on Behalf of University of Arizona Predictive markers for polyamine inhibitor cancer therapies
WO2015163832A1 (en) 2014-04-25 2015-10-29 Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. An ibuprofen and famotidine combined composition having improved stability
CA2952771A1 (en) 2014-06-18 2015-12-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Carcinoma diagnosis and treatment based on odc1 genotype
JP2018507910A (ja) 2015-02-12 2018-03-22 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ 神経芽細胞腫を治療する方法
JP2018536707A (ja) 2015-10-30 2018-12-13 キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド エフロルニチンとスリンダクの固定用量複合製剤
WO2017075576A1 (en) * 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
TWI917322B (zh) 2019-05-17 2026-03-11 美商癌症預防製藥股份有限公司 治療家族性腺瘤性瘜肉症之方法
JP2023534810A (ja) * 2020-07-15 2023-08-14 シャバー リサーチ アソシエイツ エルエルシー 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
US12514846B2 (en) 2020-07-15 2026-01-06 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach
JP2024514989A (ja) * 2021-10-21 2024-04-03 ハン ファ ファーマ カンパニー、リミテッド モンテルカストまたはその薬学的に許容可能な塩、及びレボセチリジンまたはその薬学的に許容可能な塩を含有する、安定性が改善されたフィルムコーティング錠剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4802924A (en) 1986-06-19 1989-02-07 Colorcon, Inc. Coatings based on polydextrose for aqueous film coating of pharmaceutical food and confectionary products
HU196775B (en) 1986-08-05 1989-01-30 Richter Gedeon Vegyeszet Process for production of morfologically unique new modifications of famotidin and medical compositions containing such substances
CA2144155A1 (en) * 1992-09-29 1994-04-14 Robert T. Sims Ibuprofen-h2 antagonist combinations
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US6251945B1 (en) 1999-01-14 2001-06-26 Knoll Aktiengesellschaft Pharmaceutical mixture comprising a combination of a profen and other active compounds
DE10003757A1 (de) 2000-01-28 2001-08-02 Knoll Ag Ibuprofen-Wirkstoffzubereitung
DK1411900T4 (da) * 2001-06-01 2014-01-27 Pozen Inc Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs
DE10153934A1 (de) 2001-11-06 2003-05-22 Basf Ag Verfahren zur Kristallisation von Profenen
CA2554012A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
JP2006076956A (ja) * 2004-09-10 2006-03-23 Taiyo Yakuhin Kogyo Kk 胃炎の治療・予防用配合剤
WO2007012019A2 (en) * 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
DE102005049001A1 (de) 2005-10-11 2007-04-12 Basf Ag Verfahren zur Herstellung von direkttablettierbaren Ibuprofen-Formulierungen

Also Published As

Publication number Publication date
CA2657928A1 (en) 2008-01-24
EP2043637B1 (en) 2012-01-04
JP2009543885A (ja) 2009-12-10
NZ574200A (en) 2011-02-25
WO2008011426A3 (en) 2008-12-04
IL196425A0 (en) 2009-11-18
ES2380747T3 (es) 2012-05-18
EP2043637A4 (en) 2009-11-25
ATE539747T1 (de) 2012-01-15
IL196425A (en) 2014-07-31
AU2007275360B2 (en) 2013-05-16
EP2043637A2 (en) 2009-04-08
EP2043637B8 (en) 2012-03-28
PT2043637E (pt) 2012-04-12
PL2043637T3 (pl) 2012-06-29
AU2007275360A1 (en) 2008-01-24
DK2043637T3 (da) 2012-05-07
EP2438919A1 (en) 2012-04-11
WO2008011426A2 (en) 2008-01-24
CA2657928C (en) 2014-12-02

Similar Documents

Publication Publication Date Title
CA2657928C (en) Methods and medicaments for administration of ibuprofen
US8067451B2 (en) Methods and medicaments for administration of ibuprofen
US8501228B2 (en) Stable compositions of famotidine and ibuprofen
US20140066485A1 (en) Medicaments containing famotidine and ibuprofen and administration of same
CN101516368B (zh) 用于施用布洛芬的方法和药物
BRPI0708059A2 (pt) formulação de niacina de baixo rubor
US20080021078A1 (en) Methods and medicaments for administration of ibuprofen
AU703242B2 (en) Film coated tablet of paracetamol and domperidone
US20150224056A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
US20140322313A1 (en) Pharmaceutical compositions of ibuprofen and an h2 receptor antagonist
HK1169038A (en) Compositions comprising famotidine and ibuprofen as well as compositions comprising 25 mg to 28 mg famotidine
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
AU2006269894B2 (en) Medicaments containing famotidine and ibuprofen and administration of same

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: GRUENENTHAL S.A. (PA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements